MOTS-C and SS-31 for Enhanced Athletes, Labs Included

Every vendor blog selling mitochondrial peptides leads with the same line: SS-31 and MOTS-C are the future of cellular energy and longevity. None of them tell you what either compound does to your bloodwork, which is the one thing a bodybuilder running these alongside a cycle actually needs to know.

That gap exists because the honest answer is awkward. SS-31 (elamipretide) barely moves any standard blood marker. MOTS-C moves the metabolic ones, glucose, insulin, HbA1c, but almost all of that evidence is from mice. If you want a guide that respects what the data says and what it does not, this is it.

This article covers what each peptide actually does at the cellular level, what your labs should look like if you run them, how MOTS-C stacks up against MK-677 for the insulin-resistance problem most enhanced athletes face, the exact panel to pull and when, and the messy 2026 regulatory and sourcing picture.

What SS-31 and MOTS-C actually do

These two get marketed as a pair, but they work on completely different problems. Lumping them together is the first mistake most write-ups make.

SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that crosses into the cell and concentrates several thousand-fold on the inner mitochondrial membrane, where it binds a phospholipid called cardiolipin (Szeto, 2014). Cardiolipin is the structural glue that holds the electron transport chain supercomplexes together. When it gets oxidized, those supercomplexes fall apart, electron leakage rises, and reactive oxygen species (ROS) production climbs. SS-31 protects cardiolipin from that peroxidation, which keeps the chain assembled and cuts ROS at the source rather than scavenging free radicals after the fact. That distinction matters: it is mechanistically different from swallowing vitamin C or NAC.

MOTS-C is a different animal entirely. It is a 16-amino-acid peptide your own mitochondria encode, written into a small reading frame inside the 12S ribosomal RNA gene (Lee et al., 2015). Your body releases it in response to exercise and metabolic stress. Its main trick is activating AMPK, the cellular energy sensor, through the folate-AICAR pathway. The clever part is that it activates AMPK without depleting cellular ATP, which most pharmacological AMPK activators cannot do. Downstream, AMPK drives more GLUT4 to the muscle cell surface, so glucose gets pulled out of the blood through a route that does not depend on insulin signaling. That is why people call it an exercise mimetic.

So one peptide is about mitochondrial quality and oxidative stress, the other is about glucose and insulin sensitivity. Keep that split in your head, because it is exactly the split you will see (or fail to see) on your labs.

What MOTS-C does to your glucose, insulin, and HbA1c

This is the section that matters for monitoring, because MOTS-C targets the metabolic markers a standard panel already measures.

In the original characterization, MOTS-C treatment in high-fat-diet mice prevented diet-induced obesity and insulin resistance, improved insulin-stimulated glucose disposal on a clamp, and increased GLUT4 translocation in muscle (Lee et al., 2015). A follow-up metabolomic study found MOTS-C in obese mice lowered blood glucose within days, nudged insulin and leptin down, and shifted plasma lipids toward a less insulin-resistant pattern (Kim et al., 2019). The famous longevity result comes from the exercise-capacity work: old mice given MOTS-C ran roughly twice as long and more than twice as far on a treadmill as untreated old controls (Reynolds et al., 2021).

Read those sentences again and notice the word "mice." That is not an accident. Nearly all the efficacy data for MOTS-C is preclinical.

The human evidence is observational and pointed in a coherent direction, but it cannot prove causation. In obese children and adolescents, circulating MOTS-C ran lower than in lean controls and correlated inversely with fasting insulin, HOMA-IR, and HbA1c (Du et al., 2018). Cross-sectional work in adults links lower endogenous MOTS-C to worse glycemic control. The one wrinkle worth flagging honestly: a 2025 cohort found MOTS-C positively correlated with HOMA-IR in obese individuals, which the authors read as compensatory upregulation, the body cranking out more MOTS-C as insulin resistance worsens, much like insulin itself rises before beta cells give out (Ozkaya et al., 2025). The literature is not perfectly tidy.

The only completed interventional human trial used CB4211, an engineered MOTS-C analog with a longer half-life, not the native peptide. In 11 NAFLD patients over 28 days it cleared its safety endpoint and dropped ALT about 25%, but liver fat reduction was not statistically different from placebo. That tells you very little about whether the native 16-amino-acid peptide, dosed at 5 to 10 mg by the grey-market crowd, will move a healthy athlete's HOMA-IR.

A worked HOMA-IR example

HOMA-IR is the marker to anchor on, and you can calculate it yourself from two numbers most panels already give you.

The formula is HOMA-IR = (fasting glucose in mmol/L x fasting insulin in mU/L) / 22.5. If your glucose is reported in mg/dL, divide it by 18 first to get mmol/L.

Take a lean natural athlete: glucose 4.8 mmol/L, insulin 6 mU/L. HOMA-IR = (4.8 x 6) / 22.5 = 1.28. That is comfortably normal.

Now the same athlete six months into 25 mg/day MK-677 on a bulk: glucose 5.6 mmol/L, insulin 14 mU/L. HOMA-IR = (5.6 x 14) / 22.5 = 3.48. That sits in clinically insulin-resistant territory, knocking on prediabetes.

Below 1.9 is normal, 2.0 to 2.9 is early insulin resistance, and above 3.0 is the range worth acting on. The reason this calculation matters is that it turns two cheap, routine numbers into the single most useful early-warning marker for anyone running GH secretagogues. MOTS-C, in theory, works against exactly that drift.

What SS-31 does to inflammation and oxidative stress markers

Here is where you have to manage expectations, because SS-31's marketing wildly outruns its bloodwork evidence.

The mechanism is real and well-characterized. In explanted failing human hearts, elamipretide improved oxygen flux and Complex I and IV activity, with no effect on healthy hearts, which confirms it acts selectively on dysfunctional mitochondria (Chatfield et al., 2019). In a single-dose human trial, older adults saw skeletal muscle ATP production rise about 27% versus 12% on placebo, though the effect reversed within a week without continued dosing (Roshanravan et al., 2021). In aged mice, eight weeks of SS-31 reversed lipid-peroxidation markers, restored glutathione status, and nearly doubled treadmill endurance (Campbell et al., 2019).

Now the awkward part. No human randomized trial has reported hs-CRP, IL-6, TNF-alpha, or total CK as an outcome for SS-31. The anti-inflammatory effect on CRP and cytokines is robust in animal and canine heart-failure models, but the jump to a human blood test is an inference, not a finding. And the cleanest test of the muscle-damage angle went the wrong way: in the EMBRACE STEMI trial, elamipretide did not significantly reduce cardiac CK-MB after a heart attack, the exact ischemia-reperfusion damage the preclinical work targeted (Gibson et al., 2016).

It gets more sobering. MMPOWER-3 enrolled 218 patients with genetically confirmed primary mitochondrial myopathy, the population with the single strongest mechanistic rationale, dosed 40 mg/day for 24 weeks, and missed both primary endpoints (the 6-minute walk test came in at -3.2 m, p=0.69) (Karaa et al., 2023). A post-hoc subgroup signal in certain genotypes is hypothesis-generating at best.

The September 2025 FDA accelerated approval as Forzinity is real, but read it for what it is: approval for Barth syndrome, an ultra-rare genetic cardiolipin disorder, on a surrogate endpoint of knee-extensor strength (Shirley, 2026). That is genuine validation of the cardiolipin mechanism in the one disease where the cardiolipin defect is primary and genetic. It is not a green light for healthy athletes, and it does not mean SS-31 will show up on your labs.

The honest takeaway: there is currently no blood marker that confirms SS-31 is doing anything. Its approval rests on a functional strength test, not a number you can draw. If you run it, you are tracking how you feel and recover, not a lab value.

MOTS-C vs MK-677 for insulin sensitivity

This is the comparison that actually has practical teeth, because the two compounds push the same marker in opposite directions.

MK-677's metabolic cost is one of the best-documented things in the secretagogue literature. In a 12-month RCT in healthy older adults, 25 mg/day raised fasting glucose by about 5 mg/dL, lifted HbA1c by 0.2% with eight subjects crossing into the prediabetic range, and measurably worsened insulin sensitivity (Nass et al., 2008). An earlier study saw fasting glucose climb from 5.4 to 6.8 mmol/L in just four weeks, a 26% jump (Chapman et al., 1996). The mechanism is sustained, non-pulsatile GH elevation blunting insulin signaling. For scale, pathological GH excess in acromegaly drives frank diabetes in roughly 28% of patients at diagnosis (Alexopoulou et al., 2014). MK-677 is a subclinical version of that same pressure.

MOTS-C works the mirror image. Same target tissue, skeletal muscle. Same endpoint, GLUT4 and glucose clearance. But it gets there through AMPK, the metformin-like pathway, instead of GH receptor signaling. On paper it is the natural metabolic offset to a GH-secretagogue stack.

On paper. The evidence asymmetry is enormous and you should weigh it honestly. MK-677 has multiple human RCTs quantifying its glucose damage. MOTS-C has mouse efficacy and human correlations, and zero co-administration data. Nobody has run a trial asking whether MOTS-C can claw back the HOMA-IR that MK-677 adds. The mechanistic logic is clean, but "mechanistically complementary" is not the same as "proven to work," and you should not run MK-677 recklessly on the assumption that MOTS-C cancels the cost.

If your real goal is GH-secretagogue benefit without the glucose hit, the better-evidenced lever is tesamorelin, whose pulsatile GHRH mechanism keeps fasting glucose nearly neutral in responders, or simply pairing CJC-1295 and ipamorelin at sane doses. MOTS-C is the interesting experimental add-on, not the cornerstone. For the full picture on how GH and MK-677 wreck insulin sensitivity, see our GH and insulin resistance article and the MK-677 blood sugar guide.

Where these fit for TRT and GH-secretagogue users

The enhanced-athlete case for these peptides is mechanistic, not proven. Worth being clear about which is which.

For MOTS-C, the rationale is metabolic insurance. Anabolic steroids and GH secretagogues both push insulin resistance, and circulating MOTS-C declines with age, so the 38-year-old who has been cycling for a decade is metabolically worse positioned than he was at 22 on two fronts at once. AMPK activation is the same axis metformin works on, without metformin's mTOR suppression that lifters worry about blunting hypertrophy. That is a coherent story. It is not a clinical result.

For SS-31, the angle is cardioprotection. Supraphysiologic androgens demonstrably raise mitochondrial ROS and oxidative damage in cardiac tissue in animal models (Carteri et al., 2021), and AAS users carry higher resting oxidative-stress markers than non-users (Arazi et al., 2017). SS-31's mechanism is specifically reducing that kind of mitochondrial ROS. The logic runs: AAS raises cardiac ROS, SS-31 lowers mitochondrial ROS, so SS-31 might protect the AAS-using heart. That chain is reasonable. But every link past the first is extrapolation, and no study has tested SS-31 in any athlete, enhanced or natural.

None of these stacks (MOTS-C, SS-31, tesamorelin, MK-677) have human data in resistance-trained PED users. If you run them, you are an experiment with a sample size of one, which is exactly why the bloodwork matters.

The pre-cycle and on-cycle blood panel

Because SS-31 has no efficacy marker and MOTS-C targets the metabolic panel, your monitoring strategy is really a metabolic and safety panel that doubles as your steroid-cycle baseline. Here is what to pull and when.

Baseline, before the first injection: fasting glucose, fasting insulin (calculate HOMA-IR from the two), HbA1c, a full lipid panel (LDL, HDL, triglycerides, total cholesterol), hs-CRP, creatine kinase, a CBC, and a metabolic panel with ALT, AST, and creatinine. If you are stacking GH secretagogues, add IGF-1, though understand that reflects the secretagogue, not the mitochondrial peptides.

Week 4: repeat fasting glucose, fasting insulin, and the liver and kidney markers (ALT, AST, creatinine). This is your early read and your safety check.

Week 8: fasting glucose, fasting insulin, HOMA-IR, lipids.

Week 12: the full baseline panel again, including HbA1c, which moves slowly and needs the full quarter to show anything.

A simple decision tree for whether it is working

At week 4, ask: is fasting insulin down more than 10% from baseline, and are ALT, AST, and creatinine stable? If yes, continue. If liver or kidney markers are climbing, stop and find out why before anything else.

At week 8, ask: is HOMA-IR trending down, toward 2.0 if it started high, or at least 15% below baseline? A clear drop is your efficacy signal. If HOMA-IR is flat or worse with no confounder (no new AAS, no big calorie surplus), the peptide is probably not doing much at your dose.

At week 12, ask: is HbA1c stable or lower, and are lipids holding? If yes, the cycle did its job. Run a confirmation panel four weeks off to see whether the improvement persists. If HbA1c is climbing despite MOTS-C, look hard at what else changed, usually MK-677 on the stack or a bulk.

Stop immediately, regardless of timing, if ALT or AST exceeds three times the upper limit of normal, CK spikes with muscle symptoms, or you get a fever or systemic reaction after an injection. That last one is not paranoia: grey-market peptides reach your mitochondria directly, and endotoxin contamination is a documented risk with research-grade product.

The 2026 sourcing and regulatory reality

This is the part the vendor blogs skip, and in 2026 it changed fast.

SS-31 crossed into the regulated world. Elamipretide was granted FDA accelerated approval as Forzinity in September 2025 for Barth syndrome, the first-ever approved mitochondria-targeted drug, distributed through a single specialty pharmacy (U.S. FDA, 2025). The paradox for the grey market is that approval narrows access rather than widening it: once a drug is commercially available, 503A compounding pharmacies generally cannot produce what is "essentially a copy" of it. So the only non-prescription route to SS-31 is research-grade peptide, and selling that for human use remains a federal violation.

MOTS-C sits in a more precarious spot. It was reportedly removed from the FDA's 503A compounding Category 2 in 2026 and is on the agenda for a Pharmacy Compounding Advisory Committee review in July 2026, alongside other popular peptides, to decide whether it belongs on the compoundable bulks list. As of writing it is not authorized for compounding under 503A or 503B. The specific dates and list movements here are reported by regulatory trackers and were not all directly confirmable on FDA's live pages, so treat the exact timeline as provisional and verify before you act on it.

Two more things you cannot ignore. First, purity: independent testing of grey-market peptides repeatedly turns up products well below labeled purity, and an HPLC certificate does not screen for bacterial endotoxin, residual solvents, or heavy metals. With a compound that targets the inner mitochondrial membrane, contamination is not a trivial risk. Second, doping status: MOTS-C is explicitly named on the 2026 WADA Prohibited List as an AMPK activator under S4.4.1, prohibited at all times, with no TUE available. SS-31 is not explicitly listed, but as an unapproved substance it almost certainly falls under the S0 catch-all, so any tested athlete should assume both are off-limits and career-ending.

Practical recommendations

If you are going to experiment, do it like someone who wants to know the answer. Pull a real baseline before the first pin, not after. Track HOMA-IR as your primary number for MOTS-C and accept that SS-31 has no number, only a feel. Do not run MK-677 hard on the theory that MOTS-C neutralizes it, because nobody has shown that it does. Source matters more here than with almost any other compound, because the target is your mitochondria and the contamination risk is real. And if you compete in a tested sport, do not touch either one.

Key takeaways

• SS-31 and MOTS-C solve different problems. SS-31 is mitochondrial quality and oxidative stress; MOTS-C is glucose and insulin sensitivity. Do not lump them together.
• MOTS-C is the one that shows up on a standard panel. Track fasting glucose, fasting insulin, HOMA-IR, and HbA1c. Almost all efficacy evidence is from mice, with human data limited to correlations.
• SS-31 has no blood marker that confirms it is working. Its FDA approval rests on a muscle-strength test in Barth syndrome, and human trials in broader mitochondrial disease (MMPOWER-3) and post-MI muscle damage (EMBRACE STEMI) missed their endpoints.
• The MOTS-C vs MK-677 logic is clean but unproven. MK-677 reliably worsens HOMA-IR; MOTS-C theoretically offsets it via AMPK, but no co-administration trial exists.
• Calculate your own HOMA-IR: (glucose mmol/L x insulin mU/L) / 22.5. Above 3.0 is the range to act on, and high-dose MK-677 routinely pushes athletes there.
• Run a baseline, week 4, week 8, and week 12 panel. Stop for ALT/AST above 3x normal, CK spikes with symptoms, or any post-injection systemic reaction.
• 2026 regulatory reality: SS-31 is now approved as Forzinity (which limits compounding access), MOTS-C faces FDA compounding review, grey-market purity is unreliable, and MOTS-C is explicitly WADA-banned.

---

References

1. Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S.-J., Mehta, H., Hevener, A. L., de Cabo, R., & Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454. PubMed

2. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., Joly, J. H., Mitchell, C. J., Cameron-Smith, D., Lu, R., Cohen, P., Graham, N. A., Benayoun, B. A., Merry, T. L., & Lee, C. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), 470. PubMed

3. Kim, S.-J., Miller, B., Mehta, H. H., Xiao, J., Wan, J., Arpawong, T. E., Yen, K., & Cohen, P. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(13), e14171. PubMed

4. Du, C., Zhang, C., Wu, W., Liang, Y., Wang, A., Wu, S., Zhao, Y., Hou, L., Ning, Q., & Luo, X. (2018). Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatric Diabetes, 19(6), 1058-1064. PubMed

5. Ozkaya, D. Y., Haymana, C., Demirci, I., et al. (2025). MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction. Archives of Endocrinology and Metabolism. PubMed

6. Szeto, H. H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029-2050. PubMed

7. Chatfield, K. C., Sparagna, G. C., Chau, S., et al. (2019). Elamipretide improves mitochondrial function in the failing human heart. JACC: Basic to Translational Science, 4(2), 147-157. PubMed

8. Roshanravan, B., Liu, S. Z., Ali, A. S., Shankland, E. G., Goss, C., Amory, J. K., Robertson, H. T., Marcinek, D. J., & Conley, K. E. (2021). In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLOS ONE, 16(7), e0253849. PubMed

9. Campbell, M. D., Duan, J., Samuelson, A. T., et al. (2019). Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine, 134, 268-281. PubMed

10. Gibson, C. M., Giugliano, R. P., Kloner, R. A., et al. (2016). EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal, 37(16), 1296-1303. PubMed

11. Karaa, A., Bertini, E., Carelli, V., et al. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial. Neurology, 101(3), e238-e252. PubMed

12. Shirley, M. (2026). Elamipretide: First approval. Drugs, 86(3), 377-383. PubMed

13. Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized, controlled trial. Annals of Internal Medicine, 149(9), 601-611. PubMed

14. Chapman, I. M., Bach, M. A., Van Cauter, E., et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249-4257. PubMed

15. Alexopoulou, O., Bex, M., Kamenicky, P., Mvoula, A. B., Chanson, P., & Maiter, D. (2014). Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: A study in 148 patients. Pituitary, 17(1), 81-89. PubMed

16. Carteri, R. B., Kopczynski, A., Rodolphi, M. S., et al. (2021). Anabolic-androgenic steroids impair mitochondrial function and redox status in the heart and liver of mice. Steroids, 172, 108861. PubMed

17. Arazi, H., Mohammadjafari, H., & Asadi, A. (2017). Use of anabolic androgenic steroids produces greater oxidative stress responses to resistance exercise in strength-trained men. Toxicology Reports, 4, 282-286. PubMed

18. U.S. Food and Drug Administration. (2025, September 19). FDA grants accelerated approval to first treatment for Barth syndrome [Press release]. FDA.gov